JP2023529365A5 - - Google Patents
Info
- Publication number
- JP2023529365A5 JP2023529365A5 JP2022574520A JP2022574520A JP2023529365A5 JP 2023529365 A5 JP2023529365 A5 JP 2023529365A5 JP 2022574520 A JP2022574520 A JP 2022574520A JP 2022574520 A JP2022574520 A JP 2022574520A JP 2023529365 A5 JP2023529365 A5 JP 2023529365A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067272A JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034214P | 2020-06-03 | 2020-06-03 | |
| US63/034,214 | 2020-06-03 | ||
| PCT/US2020/050753 WO2021247064A1 (en) | 2020-06-03 | 2020-09-14 | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067272A Division JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529365A JP2023529365A (ja) | 2023-07-10 |
| JP2023529365A5 true JP2023529365A5 (https=) | 2023-09-22 |
| JP7669396B2 JP7669396B2 (ja) | 2025-04-28 |
Family
ID=72659928
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574520A Active JP7669396B2 (ja) | 2020-06-03 | 2020-09-14 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
| JP2025067272A Pending JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067272A Pending JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP4161528B1 (https=) |
| JP (2) | JP7669396B2 (https=) |
| KR (1) | KR20230031242A (https=) |
| CN (1) | CN115835868A (https=) |
| AU (1) | AU2020451061A1 (https=) |
| CA (1) | CA3184633A1 (https=) |
| CL (1) | CL2022003409A1 (https=) |
| DK (1) | DK4161528T3 (https=) |
| ES (1) | ES3058891T3 (https=) |
| FI (1) | FI4161528T3 (https=) |
| HR (1) | HRP20251457T1 (https=) |
| IL (1) | IL298200A (https=) |
| LT (1) | LT4161528T (https=) |
| MA (1) | MA59868B1 (https=) |
| MD (1) | MD4161528T2 (https=) |
| MX (1) | MX2022015220A (https=) |
| PH (1) | PH12022553276A1 (https=) |
| PL (1) | PL4161528T3 (https=) |
| PT (1) | PT4161528T (https=) |
| RS (1) | RS67440B1 (https=) |
| SI (1) | SI4161528T1 (https=) |
| SM (1) | SMT202600021T1 (https=) |
| WO (1) | WO2021247064A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| WO2024039883A2 (en) * | 2022-08-19 | 2024-02-22 | Translational Drug Development Llc | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| PL3134403T3 (pl) * | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
-
2020
- 2020-09-14 PT PT207812025T patent/PT4161528T/pt unknown
- 2020-09-14 AU AU2020451061A patent/AU2020451061A1/en active Pending
- 2020-09-14 SI SI202030684T patent/SI4161528T1/sl unknown
- 2020-09-14 DK DK20781202.5T patent/DK4161528T3/da active
- 2020-09-14 LT LTEPPCT/US2020/050753T patent/LT4161528T/lt unknown
- 2020-09-14 KR KR1020227046429A patent/KR20230031242A/ko active Pending
- 2020-09-14 EP EP20781202.5A patent/EP4161528B1/en active Active
- 2020-09-14 FI FIEP20781202.5T patent/FI4161528T3/fi active
- 2020-09-14 CA CA3184633A patent/CA3184633A1/en active Pending
- 2020-09-14 JP JP2022574520A patent/JP7669396B2/ja active Active
- 2020-09-14 HR HRP20251457TT patent/HRP20251457T1/hr unknown
- 2020-09-14 EP EP25209713.4A patent/EP4691563A3/en active Pending
- 2020-09-14 IL IL298200A patent/IL298200A/en unknown
- 2020-09-14 MD MDE20230400T patent/MD4161528T2/ro unknown
- 2020-09-14 WO PCT/US2020/050753 patent/WO2021247064A1/en not_active Ceased
- 2020-09-14 MX MX2022015220A patent/MX2022015220A/es unknown
- 2020-09-14 ES ES20781202T patent/ES3058891T3/es active Active
- 2020-09-14 PH PH1/2022/553276A patent/PH12022553276A1/en unknown
- 2020-09-14 SM SM20260021T patent/SMT202600021T1/it unknown
- 2020-09-14 MA MA59868A patent/MA59868B1/fr unknown
- 2020-09-14 RS RS20251189A patent/RS67440B1/sr unknown
- 2020-09-14 CN CN202080101656.6A patent/CN115835868A/zh active Pending
- 2020-09-14 PL PL20781202.5T patent/PL4161528T3/pl unknown
-
2022
- 2022-12-01 CL CL2022003409A patent/CL2022003409A1/es unknown
-
2025
- 2025-04-16 JP JP2025067272A patent/JP2025111539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3007386T3 (en) | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| JP2023529365A5 (https=) | ||
| US6602868B2 (en) | Treatments for restless legs syndrome | |
| JP2024507938A5 (https=) | ||
| TW200918073A (en) | Heterocyclus-substituted piperazino-dihydrothienopyrimidines | |
| JP2006523216A5 (https=) | ||
| ES2913097T3 (es) | Uso de derivados de quinolina para el tratamiento del cáncer de esófago y método de tratamiento, composición farmacéutica y equipo de los mismos | |
| JP2022514089A5 (https=) | ||
| US10875859B2 (en) | Thymoquinone/harmaline and related reaction products | |
| JP2021523220A5 (https=) | ||
| BR112020019134A2 (pt) | produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos | |
| JP2023546362A5 (https=) | ||
| JP2011512370A (ja) | ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤 | |
| JP4610481B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| US11453664B2 (en) | Thymoquinone/harmaline and related reaction products | |
| US11453665B2 (en) | Thymoquinone/harmaline and related reaction products | |
| TW201927290A (zh) | 雙層醫藥錠劑調配物 | |
| WO2024015851A1 (en) | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent | |
| US20200101050A1 (en) | Thymoquinone/harmaline and related reaction products | |
| TW200838537A (en) | Substituted quinazolines | |
| TW200410698A (en) | Methods of treating patients suffering from restless legs syndrome or related disorders | |
| CN117417281A (zh) | 抗炎、抗癌和抗血管生成化合物，药物组合物及其制备和使用方法 | |
| CN109415382A (zh) | 皮质抑素类似物 | |
| JP2004533434A (ja) | テガフール、ウラシル、フォリン酸およびシクロホスファミドの投与による腫瘍の治療方法 | |
| PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro |